XML 70 R52.htm IDEA: XBRL DOCUMENT v3.25.0.1

Segments (Tables)

12 Months Ended

Dec. 31, 2024

Summary of Segment Profit

a. Segment information:

		Year ended December 31,
		2024
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	8,034			$	5,103			$	2,463
Cost of sales			3,646				2,197				1,229
R&D expenses			633				229				112
S&M expenses			1,049				826				534
G&A expenses			410				272				150
Other loss (income)			§				3				(2	)
Segment profit		$	2,296			$	1,575			$	440

§ Represents an amount less than $0.5 million.

		Year ended December 31,
		2023
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	7,731			$	4,837			$	2,351
Cost of sales			3,421				2,111				1,191
R&D expenses			604				220				104
S&M expenses			938				767				487
G&A expenses			378				263				142
Other loss (income)			(5	)			(2	)			(39	)
Segment profit		$	2,394			$	1,478			$	465

		Year ended December 31,
		2022
		United States				Europe				International Markets
		(U.S. $ in millions)
Revenues		$	7,003			$	4,525			$	2,352
Cost of sales			3,269				1,825				1,128
R&D expenses			485				213				119
S&M expenses			879				748				467
G&A expenses			440				246				154
Other loss (income)			(3	)			(3	)			(54	)
Segment profit		$	1,934			$	1,496			$	538

		Year ended December 31,
		2024				2023				2022
		(U.S. $ in millions)
United States profit		$	2,296			$	2,394			$	1,934
Europe profit			1,575				1,478				1,496
International Markets profit			440				465				538
Total reportable segments profit			4,311				4,338				3,968
Profit of other activities			18				24				172
Amounts not allocated to segments:											—
Amortization			588				616				732
Other assets impairments, restructuring and other items			1,388				718				512
Goodwill impairment			1,280				700				2,045
Intangible assets impairments			251				350				355
Legal settlements and loss contingencies			761				1,043				2,082
Other unallocated amounts			364				502				610
Consolidated operating income (loss)			(303	)			433				(2,197	)
Financial expenses, net			981				1,057				966
Consolidated income (loss) before income taxes		$	(1,284	)		$	(624	)		$	(3,163	)

Schedule of Net Sales by Product Line

The following tables present revenues by major products and activities for each segment for the year ended December 31, 2024, 2023 and 2022:

United States segment:

		Year ended December 31,
		2024				2023				2022
		(U.S. $ in millions)
Generic products (including biosimilars)		$	3,599			$	3,138			$	3,155
AJOVY			207				211				210
AUSTEDO			1,642				1,225				963
BENDEKA and TREANDA			168				237				309
COPAXONE			242				297				359
UZEDY			117				23				—
Anda			1,536				1,577				1,471
Other*			523				1,025				536
Total		$	8,034			$	7,731			$	7,003

* Other revenues in 2024 include the sale of certain product rights. Other revenues in 2023 were mainly comprised of a $500 million upfront payment received in the fourth quarter of 2023, in connection with the collaboration on Teva’s duvakitug (anti-TL1A) asset (see note 2).

Europe segment:

		Year ended December 31,
		2024				2023				2022
		(U.S. $ in millions)
Generic products (including OTC and biosimilars)		$	3,926			$	3,664			$	3,466
AJOVY			216				160				124
COPAXONE			213				231				268
Respiratory products			244				265				273
Other*			504				516				393
Total		$	5,103			$	4,837			$	4,525

* Other revenues in 2024 and 2023 include the sale of certain product rights.

International Markets segment:

		Year ended December 31,
		2024				2023				2022
		(U.S. $ in millions)
Generic products (including OTC and biosimilars)		$	1,937			$	1,932			$	1,980
AJOVY			84				63				42
COPAXONE			48				63				64
AUSTEDO			46				15				8
Other*			349				278				257
Total		$	2,463			$	2,351			$	2,352

Schedule of Sales Percentage by Therapeutic Category

The following table represents the percentage of consolidated third party net sales to Teva’s major customers during the years ended December 31, 2024, 2023 and 2022.

		Percentage of Third Party Net Sales
		2024				2023				2022
McKesson Corporation			12	%			9	%			10	%
AmerisourceBergen Corporation			9	%			9	%			10	%

Schedule of Property, Plant and Equipment by Geographic Location

		December 31,
		2024				2023
		(U.S. $ in millions)
Israel		$	1,066			$	1,312
Germany			1,262				1,318
United States			561				596
Croatia			277				447
Czech republic			206				309
Hungary			83				279
Ireland			261				266
Other			865				1,222
Total property, plant and equipment		$	4,581			$	5,750

X

- Definition

A schedule indicating where long-lived tangible assets are located.

+ References

No definition available.

+ Details

Name:	teva_PropertyPlantAndEquipmentByGeographicAreaTableTextBlock
Namespace Prefix:	teva_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

A schedule of net sales by therapeutic category, stated as a percentage of total sales.

+ References

No definition available.

+ Details

Name:	teva_SalesPercentageByTherapeuticCategoryTableTextBlock
Namespace Prefix:	teva_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

+ Details

Name:	us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration